CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
Open Access
- 25 February 2025
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (8) , 3589-3609
Abstract
Rationale: Conventional chemotherapies for B-cell malignancies are often limited by drug resistance and significant side effects due to non-specific targeting. This research aimed to improve treatment efficacy by developing nano-delivery systems that specifically target tumor cells, thereby enhancing therapeutic precision and reducing off-target toxicity.Keywords
This publication has 67 references indexed in Scilit:
- PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicityHuman Vaccines & Immunotherapeutics, 2016
- Nanoparticle colloidal stability in cell culture media and impact on cellular interactionsChemical Society Reviews, 2015
- Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer TherapyCancer Immunology Research, 2015
- Tyrosine kinase inhibitors induce mesenchymal stem cell–mediated resistance in BCR-ABL+ acute lymphoblastic leukemiaBlood, 2015
- Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive LeukemiaClinical Cancer Research, 2013
- Cancer Cell Metabolism: One Hallmark, Many FacesCancer Discovery, 2012
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1Cancer Research, 2012
- T cell exhaustionNature Immunology, 2011
- ATM stabilizes DNA double-strand-break complexes during V(D)J recombinationNature, 2006
- HSP90 and the chaperoning of cancerNature Reviews Cancer, 2005